Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6859

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Chronic Pain
Interventions: Boston Scientific WaveWriter SCS System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 13
States / cities: Palm Desert, California • Greenwood Village, Colorado • Clermont, Florida + 10 more

Conditions: Metastatic Prostate Cancer
Interventions: AZD8359; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Orlando, Florida • East Brunswick, New Jersey • Hackensack, New Jersey + 1 more

Conditions: SARS-CoV2, COVID-19
Interventions: VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years and older
Enrollment: 5,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 145
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 172
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Chronic Pain
Interventions: Non Boston Scientific Systems, Boston Scientific Systems; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 87
States / cities: Lake Havasu City, Arizona • Phoenix, Arizona • Bakersfield, California + 76 more

Conditions: Upper Extremity Problem
Interventions: Vivistim System; Device
Lead sponsor: MicroTransponder Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Orlando, Florida • Elk Grove Village, Illinois • Evanston, Illinois + 11 more

Conditions: Renal Impairment
Interventions: RO7795081; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida • St. Petersburg, Florida

Conditions: Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Interventions: Intracept™ Intraosseous Nerve Ablation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 22
States / cities: Flagstaff, Arizona • Phoenix, Arizona • Larkspur, California + 19 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more

Conditions: Migraine
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Lemon Grove, California • Walnut Creek, California + 16 more

Conditions: Clostridioides Difficile Infection
Interventions: Ridinilazole, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 49
States / cities: Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more

Conditions: Ventricular Arrythmia, Ventricular Fibrillation, Ventricular Tachycardia
Interventions: Atala™ lead and EV-ICD Pulse Generator; Device
Lead sponsor: AtaCor Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 23 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Paresthesia-Free Fast-Acting Subperception (FAST) Study

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Patient Retrospective Outcomes (PRO)

Vivistim Registry for Paired VNS Therapy (GRASP)

A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study